The main findings of this systematic review and meta-analysis are that initiation of SGLT2 inhibitors in patients with AHF during hospitalization or early post-discharge carries 48% lower odds of rehospitalization for HF and significant improvements in patient-reported outcomes (as measured by KCCQ), without excess risk of AKI, hypotension, or hypoglycemia. The gene discussed is SLC5A2; the disease is acute kidney injury.